<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097472</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-010</org_study_id>
    <nct_id>NCT02097472</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers</brief_title>
  <official_title>A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of PATH-wSP, administered
      intramuscularly to healthy Kenyan adults and toddlers who have been primed with a
      pneumococcal conjugate vaccine (PCV).

      Additionally, the study will explore whether a measurable immune response is elicited when
      PATH-wSP is administered to healthy Kenyan adults and toddlers who have been primed with PCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      S. pneumoniae whole cell vaccine (SPWCV) is a vaccine candidate made from whole,
      unencapsulated pneumococcal cells. S. pneumoniae whole cell antigen bulk was manufactured at
      Walter Reed Army Institute of Research from strain RM200 RX1E PdT ΔlytA and is inactivated
      with beta-propiolactone. Pneumolysin, a proven virulence factor, was genetically knocked out
      in SPWCV and replaced with pneumolysoid, a derivative carrying the toxin gene with 3 point
      mutations known to abolish both cytolytic activity and complement activation. When adsorbed
      to aluminum hydroxide (alum), SPWCV is utilized as the vaccine candidate Streptococcus
      pneumoniae whole cell vaccine with aluminum hydroxide adjuvant (PATH-wSP) for clinical
      investigation. PATH-wSP has been previously tested in adults in a Phase 1 trial in the US, in
      which doses of 100 to 600 μg were given to healthy young adults in a 3-vaccination series and
      showed a favorable safety, tolerability, and immunogenicity profile.

      This study was a dose escalation and age de-escalation study, and sequential cohorts of
      subjects were identified to allow safety evaluations of dosing and ages to occur
      progressively during the study. The following PATH-wSP cohorts were defined for adult and
      toddler subjects:

        -  Adult Cohort 1: 600 μg PATH-wSP or saline

        -  Adult Cohort 2: 1000 μg PATH-wSP or saline

        -  Toddler Cohort 1: 300 μg PATH-wSP and/or active control vaccines

        -  Toddler Cohort 2: 600 μg PATH-wSP and/or active control vaccines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Headache Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes repeated use of non-narcotic pain reliever for more than 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Pain at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes use of non-narcotic pain reliever for more than 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Tenderness at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Induration at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 1: does not interfere with activity Grade 2: interferes with activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Adult Subjects Experiencing Fever at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Fever Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Cutaneous Rash Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2: includes diffuse macular/maculopapular/morbilliform rash</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Irritability Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Drowsiness Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Loss of Appetite Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Pain/Tenderness at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percent of Toddler Subjects Experiencing Induration/Swelling at Injection Site Following Vaccination</measure>
    <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
    <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA Assay</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA Assay</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against L460D Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using meso scale discovery (MSD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: Meso Scale Discovery (MSD) Assay</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PhtD Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using Meso Scale Discovery (MSD) Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against BCH0785 Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using Meso Scale Discovery (MSD) Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against StkP Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using Meso Scale Discovery (MSD) Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PcpA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using Meso Scale Discovery (MSD) Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against SPWCA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>MSD Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiuA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>MSD Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiaA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>MSD Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: MSD</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: MSD</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PhtD Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against BCH0785 Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against StkP Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PcpA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against SPWCA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PiuA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of IgG Antibodies Against PiaA Pneumococcal Protein</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to Pneumolysoid (L460D) Pneumococcal Protein Among Toddler Cohort (ELISA)</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PspA-Fam1 (ELISA)</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to L460D Pneumococcal Protein (MSD)</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PspA-Fam1 Pneumococcal Protein (MSD)</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PhtD Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to BCH0785 Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to StkP Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PcpA Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to SPWCA Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PiuA Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in IgG Response to PiaA Pneumococcal Protein</measure>
    <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
    <description>Measured using MSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Adult Subjects With Neutralizing Antibody Response to Pneumolysin</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Toddler Subjects With Neutralizing Antibody Response to Pneumolysin</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMCs) of PNC-IgG Serotypes Among Toddler Subjects</measure>
    <time_frame>12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1</time_frame>
    <description>GMCs of these IgG proteins were measured to assess potential interference of PATH-wSP with 10-valent pneumococcal conjugate vaccine (Synflorix). GMCs of Cohort 1 were measured at a different time point than those in Cohort 2, so results are presented separately.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Diptheria Booster Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Hepatitis B Booster Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Haemophilus Influenzae Type b (Hib) Booster Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Pertussis FHA and Pertussis Toxin Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Pertussis Fimbriae Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) Ratio of Tetanus Booster Immune Response Among Toddler Subjects</measure>
    <time_frame>12 weeks post vaccination 1</time_frame>
    <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>Adult Cohort 1, PATH-wSP, 600 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Cohort 1, Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Cohort 2, PATH-wSP, 1000 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Cohort 2, Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Active control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 1: Active Control Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+Active control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler Cohort 2: Active Control Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PATH-wSP</intervention_name>
    <description>Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum</description>
    <arm_group_label>Adult Cohort 1, PATH-wSP, 600 mcg</arm_group_label>
    <arm_group_label>Adult Cohort 2, PATH-wSP, 1000 mcg</arm_group_label>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Saline</arm_group_label>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix</intervention_name>
    <description>1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein</description>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 1: Active Control Only</arm_group_label>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 2: Active Control Only</arm_group_label>
    <other_name>10-valent Pneumococcal Conjugate Vaccine (PCV10)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentavac</intervention_name>
    <description>Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection.</description>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 1: Active Control Only</arm_group_label>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+Active control</arm_group_label>
    <arm_group_label>Toddler Cohort 2: Active Control Only</arm_group_label>
    <other_name>Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Adult Cohort 1, Saline</arm_group_label>
    <arm_group_label>Adult Cohort 2, Saline</arm_group_label>
    <arm_group_label>Toddler Cohort 1 PATH-wSP 300 mcg+Saline</arm_group_label>
    <arm_group_label>Toddler Cohort 1: Active Control Only</arm_group_label>
    <arm_group_label>Toddler Cohort 2 PATH-wSP 600 mcg+saline</arm_group_label>
    <arm_group_label>Toddler Cohort 2: Active Control Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy young Kenyan adults between 18 to 45 years of age

          -  Willing to provide written informed consent, able to understand comply with study
             requirements/procedures.

          -  Adult female subjects surgically sterilized or with a negative serum pregnancy test on
             enrollment and prior to each vaccination. Adult females must be willing to avoid
             becoming pregnant over the duration of the study, and must agree to employ an
             effective form of birth control for the duration of the study.

          -  Subjects willing to avoid consumption of herbal medication (including herbal
             medication taken by a mother, which may transmit to a toddler through breast milk)
             that could have effects on liver function or bleeding indices during the course of the
             study.

          -  Healthy toddlers between 12 to 15 months of age who have completed their primary EPI
             vaccines.

          -  Toddler's parent willing to provide written informed consent for subject, able to
             understand and comply with study requirements and procedures.

          -  Not premature, had a birth weight of &gt;2.5 kg, and a weight-to-height Z score of ≥ -2
             at the time of enrollment.

        Exclusion Criteria:

          -  Use of any investigational or nonregistered drug within 90 days prior and during the
             course of study participation.

          -  History of administration of any vaccine within 30 days prior to administration of
             study vaccine or planned vaccination during the course of study.

          -  History of anaphylactic shock.

          -  Positive test for malaria (blood film) at time of screening and when retested at Visit
             1.

          -  Immunosuppression or immunodeficiency, inclusive of human immunodeficiency virus, by
             medical history or by testing at screening.

          -  Chronic, clinically significant pulmonary, cardiovascular, hepatobiliary,
             gastrointestinal, renal, neurological, or hematological functional abnormality or
             major congenital defects or illness that requires medical therapy, as deemed by
             medical history or clinical assessment.

          -  Evidence of active hepatitis infection (B or C) by immunologic testing at screening.

          -  Any medical or social condition that in the opinion of the investigator will interfere
             with the study objectives or pose a risk to the study subject or may prevent the
             subject from completing the study follow-up.

          -  An employee (or first degree relative of employee) of the Sponsor, the Clinical
             Research Organization, or any investigator or site personnel.

          -  Any screening laboratory test result or vital sign measurement outside normal
             parameters and deemed by the clinician to be clinically significant, including a
             positive test for malaria.

          -  Acute illness (moderate or severe) and/or fever (tympanic temperature &gt;38°C for adults
             and &gt;37.5°C for toddlers), or any acute and limited illness requiring medical
             treatment, including the use of antibiotics and treatment for parasites.

          -  History of allergic disease or history of a serious reaction to any prior vaccination
             or known hypersensitivity to any component of the study vaccines.

          -  Disorders that require chronic administration of immune-modifying drugs within the
             past 6 months prior to the administration of the study vaccine.

          -  Administration of immunoglobulins and/or any blood products within the 6 months
             preceding enrollment in the study; or anticipation of such administration during the
             study period.

          -  Known disturbance of coagulation or other blood disorder in adult subject or in
             self/first degree relative of toddler subject; or receipt of anticoagulants in the
             past 3 weeks.

          -  History of meningitis or seizures or any neurological disorder or major psychiatric
             disorder (adult).

          -  Female subjects who are pregnant or breast-feeding.

          -  Suspicion or recent history of alcohol or substance abuse.

          -  Toddlers with evidence of congenital abnormality or developmental delay.

          -  Toddlers with evidence of fetal alcohol syndrome or history of alcohol abuse in mother
             during pregnancy.

          -  Toddlers exposed to HIV, born of an HIV infected mother, or who are HIV positive by
             either antibody or polymerase chain reaction testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nekoye Otsyula, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute/Walter Reed Project</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Medical Research Institute/Walter Reed Project</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <zip>PO Box 54-40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>May 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: approximately 12 months
Site: Single center at Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) Kombewa Clinical Research Center (CRC)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adult Cohort 1: PATH-wSP (600 mcg)</title>
          <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="P2">
          <title>Adult Cohort 2: PATH-wSP (1000 mcg)</title>
          <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="P3">
          <title>Adult Cohort: Saline</title>
          <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
        </group>
        <group group_id="P4">
          <title>Toddler Cohort 1: PATH-wSP (300 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="P5">
          <title>Toddler Cohort 1: PATH-wSP (300 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="P6">
          <title>Toddler Cohort 2: PATH-wSP (600 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="P7">
          <title>Toddler Cohort 2: PATH-wSP (600 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="P8">
          <title>Toddler Cohort: Active Control Only</title>
          <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Received Vaccination 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Received Vaccination 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Assessed for Immunogenicity</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="48"/>
                <participants group_id="P7" count="47"/>
                <participants group_id="P8" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adult Cohort: PATH-wSP (600 mcg)</title>
          <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="B2">
          <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
          <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="B3">
          <title>Adult Cohort: Saline</title>
          <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
        </group>
        <group group_id="B4">
          <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="B5">
          <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="B6">
          <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="B7">
          <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="B8">
          <title>Toddler Cohort: Active Control Only</title>
          <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="50"/>
            <count group_id="B9" value="304"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.94" spread="5.98"/>
                    <measurement group_id="B2" value="28.56" spread="8.61"/>
                    <measurement group_id="B3" value="30.39" spread="7.71"/>
                    <measurement group_id="B4" value="1.10" spread="0.09"/>
                    <measurement group_id="B5" value="1.09" spread="0.09"/>
                    <measurement group_id="B6" value="1.11" spread="0.09"/>
                    <measurement group_id="B7" value="1.13" spread="0.10"/>
                    <measurement group_id="B8" value="1.09" spread="0.09"/>
                    <measurement group_id="B9" value="5.99" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No fatigue/malaise</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: no interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Some interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No myalgia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: no interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Some interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Headache Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes repeated use of non-narcotic pain reliever for more than 24 hours.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Headache Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes repeated use of non-narcotic pain reliever for more than 24 hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: no interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Some interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Pain at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes use of non-narcotic pain reliever for more than 24 hours.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Pain at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2 includes use of non-narcotic pain reliever for more than 24 hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No pain at injection site</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: no interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Some interference limiting limb use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Tenderness at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Tenderness at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No tenderness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: no interference with activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: pain limiting limb use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Induration at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 1: does not interfere with activity Grade 2: interferes with activity</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Induration at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 1: does not interfere with activity Grade 2: interferes with activity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No induration/swelling</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: 2.5-5cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: 5.1-10cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Adult Subjects Experiencing Fever at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm</description>
          </group>
          <group group_id="O3">
            <title>Saline: Vaccination 1</title>
            <description>A single injection of saline in one arm.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Single injection of 600 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Single injection of 1000 mcg PATH-wSP in one arm, one month after initial injection</description>
          </group>
          <group group_id="O6">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in one arm, one month after initial injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Adult Subjects Experiencing Fever at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: ≥39.0 to ≤40.0 degrees Celsius</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Fever Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 1000 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Fever Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="87"/>
                    <measurement group_id="O7" value="78"/>
                    <measurement group_id="O8" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: ≥37.5 to ≤38.0 deg. Celsius</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: ≥38.1 to ≤39.0 deg. Celsius</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3: ≥39.1 to ≤40.0 deg. Celsius</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4: &gt;40.0 deg. Celsius</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Cutaneous Rash Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2: includes diffuse macular/maculopapular/morbilliform rash</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 1000 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Cutaneous Rash Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Grade 2: includes diffuse macular/maculopapular/morbilliform rash</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No cutaneous rash</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="83"/>
                    <measurement group_id="O7" value="72"/>
                    <measurement group_id="O8" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: localized macular rash</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: Diffuse rash or target lesions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Irritability Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 1000 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Irritability Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No irritability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="90"/>
                    <measurement group_id="O7" value="89"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: crying &gt;usual/normal activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: crying&gt;usual/interferes w/normal activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Drowsiness Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 1000 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Drowsiness Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No drowsiness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="95"/>
                    <measurement group_id="O7" value="94"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: drowsiness easily tolerated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: interferes with normal activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Loss of Appetite Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 1000 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Loss of Appetite Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No loss of appetite</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="85"/>
                    <measurement group_id="O7" value="88"/>
                    <measurement group_id="O8" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: eating &lt;usual/normal activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gr. 2: eating &lt;usual/interferes w/ normal activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Pain/Tenderness at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 mcg PATH-wSP: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh at first vaccination (during which subjects also received either two saline injections, or or Synflorix and Pentavac injections, in the right thigh)</description>
          </group>
          <group group_id="O2">
            <title>600 mcg PATH-wSP: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh (during which subjects also received either two saline injections, or or Synflorix and Pentavac injections, in the right thigh)</description>
          </group>
          <group group_id="O3">
            <title>Active Control: Pentavac</title>
            <description>A single injection of the active comparator vaccine Pentavac in the right thigh during the first vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Active Control: Synflorix</title>
            <description>A single injection of the active comparator vaccine Synflorix in the right thigh during the first vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Active Control: Saline</title>
            <description>One injection of saline in the left thigh during the first vaccination (during which subjects received Pentavac and Synflorix injections, but no PATH-wSP injections)</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>SA single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Pain/Tenderness at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No pain/tenderness at injection site</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="72"/>
                    <measurement group_id="O7" value="81"/>
                    <measurement group_id="O8" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: minor reactions to touch</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2: cries/protests to touch</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percent of Toddler Subjects Experiencing Induration/Swelling at Injection Site Following Vaccination</title>
        <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
        <time_frame>up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 mcg PATH-wSP: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh at first vaccination (during which subjects also received either two saline injections, or or Synflorix and Pentavac injections, in the right thigh)</description>
          </group>
          <group group_id="O2">
            <title>600 mcg PATH-wSP: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh (during which subjects also received either two saline injections, or or Synflorix and Pentavac injections, in the right thigh)</description>
          </group>
          <group group_id="O3">
            <title>Active Control: Pentavac</title>
            <description>A single injection of the active comparator vaccine Pentavac in the right thigh during the first vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Active Control: Synflorix</title>
            <description>A single injection of the active comparator vaccine Synflorix in the right thigh during the first vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Active Control: Saline</title>
            <description>One injection of saline in the left thigh during the first vaccination (during which subjects received Pentavac and Synflorix injections, but no PATH-wSP injections)</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg): Vaccination 2</title>
            <description>SA single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh 8 weeks after the first vaccination of the same dosage</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 2</title>
            <description>A single injection of saline in the left thigh 8 weeks after first vaccination visit of 2 active comparator vaccines (Synflorix and Pentavac) plus 1 saline injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percent of Toddler Subjects Experiencing Induration/Swelling at Injection Site Following Vaccination</title>
          <description>Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No induration/swelling</title>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="93"/>
                    <measurement group_id="O7" value="89"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1: Induration or edema &lt;2.5cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G2: Induration OR edema ≥2.5cm but &lt;50% surface ar</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA Assay</title>
        <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA Assay</title>
          <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2083.27" lower_limit="1638.67" upper_limit="2648.49"/>
                    <measurement group_id="O2" value="1569.91" lower_limit="1102.09" upper_limit="2236.30"/>
                    <measurement group_id="O3" value="1998.33" lower_limit="1356.41" upper_limit="2944.02"/>
                    <measurement group_id="O4" value="400.00" lower_limit="289.99" upper_limit="551.74"/>
                    <measurement group_id="O5" value="311.30" lower_limit="209.43" upper_limit="462.71"/>
                    <measurement group_id="O6" value="755.10" lower_limit="541.85" upper_limit="1052.27"/>
                    <measurement group_id="O7" value="848.61" lower_limit="612.56" upper_limit="1175.62"/>
                    <measurement group_id="O8" value="455.52" lower_limit="318.02" upper_limit="652.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2619.99" lower_limit="2015.16" upper_limit="3406.36"/>
                    <measurement group_id="O2" value="2394.59" lower_limit="1669.66" upper_limit="3434.28"/>
                    <measurement group_id="O3" value="1945.09" lower_limit="1329.56" upper_limit="2845.58"/>
                    <measurement group_id="O4" value="516.79" lower_limit="367.08" upper_limit="727.54"/>
                    <measurement group_id="O5" value="506.45" lower_limit="351.03" upper_limit="730.68"/>
                    <measurement group_id="O6" value="897.97" lower_limit="664.86" upper_limit="1212.82"/>
                    <measurement group_id="O7" value="1647.90" lower_limit="1208.09" upper_limit="2247.81"/>
                    <measurement group_id="O8" value="489.62" lower_limit="355.16" upper_limit="674.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3752.62" lower_limit="2860.91" upper_limit="4922.26"/>
                    <measurement group_id="O2" value="2933.71" lower_limit="2049.42" upper_limit="4199.55"/>
                    <measurement group_id="O3" value="1961.47" lower_limit="1301.64" upper_limit="2955.80"/>
                    <measurement group_id="O4" value="800.00" lower_limit="563.29" upper_limit="1136.18"/>
                    <measurement group_id="O5" value="732.25" lower_limit="509.87" upper_limit="1051.63"/>
                    <measurement group_id="O6" value="1510.20" lower_limit="1101.94" upper_limit="2069.72"/>
                    <measurement group_id="O7" value="2211.06" lower_limit="1592.51" upper_limit="3069.87"/>
                    <measurement group_id="O8" value="526.28" lower_limit="386.30" upper_limit="716.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA Assay</title>
        <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA Assay</title>
          <description>Measured with enzyme-linked immunosorbent assay (ELISA).</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1899.32" lower_limit="1393.87" upper_limit="2588.06"/>
                    <measurement group_id="O2" value="2042.68" lower_limit="1679.25" upper_limit="2484.75"/>
                    <measurement group_id="O3" value="1793.44" lower_limit="1404.90" upper_limit="2289.43"/>
                    <measurement group_id="O4" value="410.23" lower_limit="298.75" upper_limit="563.30"/>
                    <measurement group_id="O5" value="361.41" lower_limit="268.84" upper_limit="485.85"/>
                    <measurement group_id="O6" value="550.02" lower_limit="423.69" upper_limit="714.03"/>
                    <measurement group_id="O7" value="674.04" lower_limit="509.70" upper_limit="891.36"/>
                    <measurement group_id="O8" value="456.64" lower_limit="349.76" upper_limit="596.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2425.50" lower_limit="1929.04" upper_limit="3049.73"/>
                    <measurement group_id="O2" value="3083.33" lower_limit="2532.19" upper_limit="3754.44"/>
                    <measurement group_id="O3" value="1922.47" lower_limit="1514.36" upper_limit="2440.56"/>
                    <measurement group_id="O4" value="565.40" lower_limit="431.64" upper_limit="740.62"/>
                    <measurement group_id="O5" value="557.07" lower_limit="408.19" upper_limit="760.24"/>
                    <measurement group_id="O6" value="637.63" lower_limit="495.23" upper_limit="820.97"/>
                    <measurement group_id="O7" value="1126.67" lower_limit="831.35" upper_limit="1526.90"/>
                    <measurement group_id="O8" value="417.09" lower_limit="309.03" upper_limit="562.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3192.07" lower_limit="2609.98" upper_limit="3903.97"/>
                    <measurement group_id="O2" value="3901.23" lower_limit="2943.11" upper_limit="5171.26"/>
                    <measurement group_id="O3" value="2031.31" lower_limit="1566.67" upper_limit="2633.75"/>
                    <measurement group_id="O4" value="724.42" lower_limit="563.05" upper_limit="932.03"/>
                    <measurement group_id="O5" value="541.73" lower_limit="399.29" upper_limit="734.98"/>
                    <measurement group_id="O6" value="889.48" lower_limit="707.12" upper_limit="1118.86"/>
                    <measurement group_id="O7" value="1264.22" lower_limit="925.59" upper_limit="1726.74"/>
                    <measurement group_id="O8" value="487.03" lower_limit="359.40" upper_limit="659.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against L460D Pneumococcal Protein</title>
        <description>Measured using meso scale discovery (MSD).</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Insufficient sample</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against L460D Pneumococcal Protein</title>
          <description>Measured using meso scale discovery (MSD).</description>
          <population>Insufficient sample</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="861.27" lower_limit="661.13" upper_limit="1121.99"/>
                    <measurement group_id="O2" value="820.92" lower_limit="629.25" upper_limit="1070.97"/>
                    <measurement group_id="O3" value="908.51" lower_limit="582.64" upper_limit="1416.63"/>
                    <measurement group_id="O4" value="263.85" lower_limit="206.73" upper_limit="336.74"/>
                    <measurement group_id="O5" value="210.15" lower_limit="160.30" upper_limit="275.48"/>
                    <measurement group_id="O6" value="309.74" lower_limit="246.74" upper_limit="388.83"/>
                    <measurement group_id="O7" value="331.08" lower_limit="270.14" upper_limit="405.77"/>
                    <measurement group_id="O8" value="216.45" lower_limit="173.79" upper_limit="269.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1127.59" lower_limit="869.68" upper_limit="1461.99"/>
                    <measurement group_id="O2" value="998.09" lower_limit="777.32" upper_limit="1281.56"/>
                    <measurement group_id="O3" value="886.15" lower_limit="614.08" upper_limit="1278.77"/>
                    <measurement group_id="O4" value="329.38" lower_limit="255.01" upper_limit="425.44"/>
                    <measurement group_id="O5" value="328.35" lower_limit="253.48" upper_limit="425.33"/>
                    <measurement group_id="O6" value="386.92" lower_limit="316.53" upper_limit="472.97"/>
                    <measurement group_id="O7" value="602.20" lower_limit="489.74" upper_limit="740.49"/>
                    <measurement group_id="O8" value="247.77" lower_limit="194.90" upper_limit="314.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1391.66" lower_limit="1065.65" upper_limit="1817.41"/>
                    <measurement group_id="O2" value="1410.11" lower_limit="1014.73" upper_limit="1959.55"/>
                    <measurement group_id="O3" value="963.25" lower_limit="701.06" upper_limit="1323.49"/>
                    <measurement group_id="O4" value="462.54" lower_limit="351.01" upper_limit="609.51"/>
                    <measurement group_id="O5" value="408.40" lower_limit="318.02" upper_limit="524.46"/>
                    <measurement group_id="O6" value="631.63" lower_limit="506.72" upper_limit="787.32"/>
                    <measurement group_id="O7" value="803.61" lower_limit="630.84" upper_limit="1023.69"/>
                    <measurement group_id="O8" value="279.43" lower_limit="221.59" upper_limit="352.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: Meso Scale Discovery (MSD) Assay</title>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: Meso Scale Discovery (MSD) Assay</title>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2124.32" lower_limit="1533.58" upper_limit="2942.62"/>
                    <measurement group_id="O2" value="2129.61" lower_limit="1574.00" upper_limit="2881.35"/>
                    <measurement group_id="O3" value="2049.33" lower_limit="1457.58" upper_limit="2881.30"/>
                    <measurement group_id="O4" value="175.80" lower_limit="122.62" upper_limit="252.03"/>
                    <measurement group_id="O5" value="174.35" lower_limit="119.81" upper_limit="253.71"/>
                    <measurement group_id="O6" value="202.89" lower_limit="145.92" upper_limit="282.09"/>
                    <measurement group_id="O7" value="217.24" lower_limit="154.08" upper_limit="306.29"/>
                    <measurement group_id="O8" value="177.29" lower_limit="127.64" upper_limit="246.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3149.80" lower_limit="2268.50" upper_limit="4373.47"/>
                    <measurement group_id="O2" value="3442.17" lower_limit="2582.70" upper_limit="4587.64"/>
                    <measurement group_id="O3" value="2105.22" lower_limit="1473.42" upper_limit="3007.94"/>
                    <measurement group_id="O4" value="283.38" lower_limit="203.73" upper_limit="394.15"/>
                    <measurement group_id="O5" value="294.98" lower_limit="203.95" upper_limit="426.66"/>
                    <measurement group_id="O6" value="272.19" lower_limit="204.41" upper_limit="362.44"/>
                    <measurement group_id="O7" value="420.45" lower_limit="285.84" upper_limit="618.44"/>
                    <measurement group_id="O8" value="167.21" lower_limit="112.78" upper_limit="247.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3469.35" lower_limit="2725.55" upper_limit="4416.14"/>
                    <measurement group_id="O2" value="4607.95" lower_limit="3491.22" upper_limit="6081.90"/>
                    <measurement group_id="O3" value="2323.41" lower_limit="1752.55" upper_limit="3080.21"/>
                    <measurement group_id="O4" value="367.01" lower_limit="265.16" upper_limit="507.99"/>
                    <measurement group_id="O5" value="338.19" lower_limit="230.39" upper_limit="496.43"/>
                    <measurement group_id="O6" value="371.56" lower_limit="279.50" upper_limit="493.95"/>
                    <measurement group_id="O7" value="518.77" lower_limit="365.33" upper_limit="736.65"/>
                    <measurement group_id="O8" value="186.84" lower_limit="126.04" upper_limit="276.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PhtD Pneumococcal Protein</title>
        <description>Measured using Meso Scale Discovery (MSD) Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PhtD Pneumococcal Protein</title>
          <description>Measured using Meso Scale Discovery (MSD) Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841.63" lower_limit="626.89" upper_limit="1129.94"/>
                    <measurement group_id="O2" value="784.56" lower_limit="606.58" upper_limit="1014.75"/>
                    <measurement group_id="O3" value="775.26" lower_limit="531.41" upper_limit="1130.99"/>
                    <measurement group_id="O4" value="426.11" lower_limit="313.40" upper_limit="579.35"/>
                    <measurement group_id="O5" value="403.13" lower_limit="289.64" upper_limit="561.09"/>
                    <measurement group_id="O6" value="466.20" lower_limit="337.37" upper_limit="644.21"/>
                    <measurement group_id="O7" value="497.28" lower_limit="383.30" upper_limit="645.15"/>
                    <measurement group_id="O8" value="434.86" lower_limit="331.26" upper_limit="570.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.14" lower_limit="576.12" upper_limit="1222.24"/>
                    <measurement group_id="O2" value="868.55" lower_limit="655.40" upper_limit="1151.03"/>
                    <measurement group_id="O3" value="775.29" lower_limit="535.14" upper_limit="1123.21"/>
                    <measurement group_id="O4" value="563.55" lower_limit="429.28" upper_limit="739.83"/>
                    <measurement group_id="O5" value="491.70" lower_limit="361.58" upper_limit="668.64"/>
                    <measurement group_id="O6" value="577.47" lower_limit="434.14" upper_limit="768.11"/>
                    <measurement group_id="O7" value="654.21" lower_limit="512.33" upper_limit="835.39"/>
                    <measurement group_id="O8" value="513.83" lower_limit="390.75" upper_limit="675.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="890.67" lower_limit="627.43" upper_limit="1264.34"/>
                    <measurement group_id="O2" value="982.10" lower_limit="710.87" upper_limit="1356.82"/>
                    <measurement group_id="O3" value="872.62" lower_limit="603.52" upper_limit="1261.71"/>
                    <measurement group_id="O4" value="804.59" lower_limit="612.11" upper_limit="1057.60"/>
                    <measurement group_id="O5" value="704.46" lower_limit="552.58" upper_limit="898.09"/>
                    <measurement group_id="O6" value="767.31" lower_limit="578.07" upper_limit="1018.48"/>
                    <measurement group_id="O7" value="1074.36" lower_limit="844.35" upper_limit="1367.04"/>
                    <measurement group_id="O8" value="679.80" lower_limit="519.10" upper_limit="890.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against BCH0785 Pneumococcal Protein</title>
        <description>Measured using Meso Scale Discovery (MSD) Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against BCH0785 Pneumococcal Protein</title>
          <description>Measured using Meso Scale Discovery (MSD) Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1566.50" lower_limit="1035.43" upper_limit="2369.96"/>
                    <measurement group_id="O2" value="1145.05" lower_limit="909.05" upper_limit="1442.33"/>
                    <measurement group_id="O3" value="1236.11" lower_limit="819.09" upper_limit="1865.46"/>
                    <measurement group_id="O4" value="400.58" lower_limit="294.10" upper_limit="545.61"/>
                    <measurement group_id="O5" value="271.66" lower_limit="200.93" upper_limit="367.30"/>
                    <measurement group_id="O6" value="281.66" lower_limit="209.24" upper_limit="379.16"/>
                    <measurement group_id="O7" value="372.53" lower_limit="277.67" upper_limit="499.79"/>
                    <measurement group_id="O8" value="288.13" lower_limit="206.26" upper_limit="402.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1665.26" lower_limit="1070.16" upper_limit="2591.29"/>
                    <measurement group_id="O2" value="1367.52" lower_limit="1050.00" upper_limit="1781.04"/>
                    <measurement group_id="O3" value="1224.22" lower_limit="787.13" upper_limit="1904.02"/>
                    <measurement group_id="O4" value="504.49" lower_limit="372.64" upper_limit="682.99"/>
                    <measurement group_id="O5" value="364.39" lower_limit="279.71" upper_limit="474.72"/>
                    <measurement group_id="O6" value="373.57" lower_limit="288.65" upper_limit="483.48"/>
                    <measurement group_id="O7" value="526.34" lower_limit="385.99" upper_limit="717.73"/>
                    <measurement group_id="O8" value="328.03" lower_limit="238.52" upper_limit="451.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1808.37" lower_limit="1220.45" upper_limit="2679.52"/>
                    <measurement group_id="O2" value="1713.83" lower_limit="1263.06" upper_limit="2325.47"/>
                    <measurement group_id="O3" value="1340.75" lower_limit="972.21" upper_limit="1849.00"/>
                    <measurement group_id="O4" value="561.60" lower_limit="408.05" upper_limit="772.93"/>
                    <measurement group_id="O5" value="480.18" lower_limit="373.03" upper_limit="618.11"/>
                    <measurement group_id="O6" value="470.01" lower_limit="350.35" upper_limit="630.53"/>
                    <measurement group_id="O7" value="716.82" lower_limit="538.77" upper_limit="953.71"/>
                    <measurement group_id="O8" value="394.37" lower_limit="288.87" upper_limit="538.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against StkP Pneumococcal Protein</title>
        <description>Measured using Meso Scale Discovery (MSD) Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against StkP Pneumococcal Protein</title>
          <description>Measured using Meso Scale Discovery (MSD) Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1406.04" lower_limit="901.16" upper_limit="2193.77"/>
                    <measurement group_id="O2" value="1140.55" lower_limit="863.69" upper_limit="1506.15"/>
                    <measurement group_id="O3" value="1263.61" lower_limit="819.76" upper_limit="1947.76"/>
                    <measurement group_id="O4" value="204.58" lower_limit="146.61" upper_limit="285.48"/>
                    <measurement group_id="O5" value="130.62" lower_limit="98.14" upper_limit="173.85"/>
                    <measurement group_id="O6" value="157.58" lower_limit="113.59" upper_limit="218.61"/>
                    <measurement group_id="O7" value="229.15" lower_limit="169.00" upper_limit="310.70"/>
                    <measurement group_id="O8" value="161.89" lower_limit="119.32" upper_limit="219.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1632.87" lower_limit="1003.67" upper_limit="2656.52"/>
                    <measurement group_id="O2" value="1311.45" lower_limit="973.06" upper_limit="1767.52"/>
                    <measurement group_id="O3" value="1308.29" lower_limit="825.65" upper_limit="2073.06"/>
                    <measurement group_id="O4" value="278.64" lower_limit="204.21" upper_limit="380.18"/>
                    <measurement group_id="O5" value="164.27" lower_limit="124.79" upper_limit="216.24"/>
                    <measurement group_id="O6" value="187.67" lower_limit="140.60" upper_limit="250.51"/>
                    <measurement group_id="O7" value="295.14" lower_limit="219.22" upper_limit="397.35"/>
                    <measurement group_id="O8" value="180.93" lower_limit="132.20" upper_limit="247.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1753.89" lower_limit="1138.27" upper_limit="2702.47"/>
                    <measurement group_id="O2" value="1620.05" lower_limit="1203.93" upper_limit="2180.01"/>
                    <measurement group_id="O3" value="1430.78" lower_limit="985.89" upper_limit="2076.42"/>
                    <measurement group_id="O4" value="351.25" lower_limit="255.61" upper_limit="482.66"/>
                    <measurement group_id="O5" value="230.51" lower_limit="183.42" upper_limit="289.68"/>
                    <measurement group_id="O6" value="273.84" lower_limit="205.92" upper_limit="364.16"/>
                    <measurement group_id="O7" value="396.24" lower_limit="297.85" upper_limit="527.14"/>
                    <measurement group_id="O8" value="217.32" lower_limit="162.69" upper_limit="290.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PcpA Pneumococcal Protein</title>
        <description>Measured using Meso Scale Discovery (MSD) Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PcpA Pneumococcal Protein</title>
          <description>Measured using Meso Scale Discovery (MSD) Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1677.20" lower_limit="1248.67" upper_limit="2252.80"/>
                    <measurement group_id="O2" value="1016.49" lower_limit="757.20" upper_limit="1364.57"/>
                    <measurement group_id="O3" value="1436.97" lower_limit="996.44" upper_limit="2072.26"/>
                    <measurement group_id="O4" value="316.39" lower_limit="202.24" upper_limit="494.97"/>
                    <measurement group_id="O5" value="350.52" lower_limit="218.29" upper_limit="562.87"/>
                    <measurement group_id="O6" value="355.69" lower_limit="206.59" upper_limit="612.41"/>
                    <measurement group_id="O7" value="356.24" lower_limit="224.23" upper_limit="565.95"/>
                    <measurement group_id="O8" value="254.77" lower_limit="152.06" upper_limit="426.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1523.84" lower_limit="1045.11" upper_limit="2221.85"/>
                    <measurement group_id="O2" value="904.99" lower_limit="670.76" upper_limit="1221.03"/>
                    <measurement group_id="O3" value="1461.34" lower_limit="1064.83" upper_limit="2005.48"/>
                    <measurement group_id="O4" value="354.49" lower_limit="222.21" upper_limit="565.50"/>
                    <measurement group_id="O5" value="327.75" lower_limit="203.97" upper_limit="526.65"/>
                    <measurement group_id="O6" value="473.66" lower_limit="290.78" upper_limit="771.55"/>
                    <measurement group_id="O7" value="344.10" lower_limit="211.00" upper_limit="561.19"/>
                    <measurement group_id="O8" value="297.33" lower_limit="181.65" upper_limit="486.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1497.72" lower_limit="1127.58" upper_limit="1989.36"/>
                    <measurement group_id="O2" value="950.83" lower_limit="668.08" upper_limit="1353.25"/>
                    <measurement group_id="O3" value="1728.30" lower_limit="1234.67" upper_limit="2419.29"/>
                    <measurement group_id="O4" value="375.72" lower_limit="234.90" upper_limit="600.97"/>
                    <measurement group_id="O5" value="342.08" lower_limit="216.65" upper_limit="540.12"/>
                    <measurement group_id="O6" value="441.77" lower_limit="265.98" upper_limit="733.75"/>
                    <measurement group_id="O7" value="434.85" lower_limit="259.39" upper_limit="729.01"/>
                    <measurement group_id="O8" value="392.99" lower_limit="236.60" upper_limit="652.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against SPWCA Pneumococcal Protein</title>
        <description>MSD Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against SPWCA Pneumococcal Protein</title>
          <description>MSD Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1707.99" lower_limit="1209.54" upper_limit="2411.84"/>
                    <measurement group_id="O2" value="1398.09" lower_limit="969.28" upper_limit="2016.60"/>
                    <measurement group_id="O3" value="1321.49" lower_limit="1075.42" upper_limit="1623.87"/>
                    <measurement group_id="O4" value="664.34" lower_limit="580.83" upper_limit="759.85"/>
                    <measurement group_id="O5" value="632.54" lower_limit="552.55" upper_limit="724.12"/>
                    <measurement group_id="O6" value="615.81" lower_limit="530.49" upper_limit="714.86"/>
                    <measurement group_id="O7" value="665.59" lower_limit="596.55" upper_limit="742.63"/>
                    <measurement group_id="O8" value="652.61" lower_limit="581.79" upper_limit="732.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1660.20" lower_limit="1310.34" upper_limit="2103.47"/>
                    <measurement group_id="O2" value="1359.27" lower_limit="1049.52" upper_limit="1760.45"/>
                    <measurement group_id="O3" value="1263.81" lower_limit="1026.75" upper_limit="1555.61"/>
                    <measurement group_id="O4" value="778.54" lower_limit="680.41" upper_limit="890.82"/>
                    <measurement group_id="O5" value="717.62" lower_limit="649.35" upper_limit="793.07"/>
                    <measurement group_id="O6" value="728.65" lower_limit="639.50" upper_limit="830.22"/>
                    <measurement group_id="O7" value="771.90" lower_limit="682.33" upper_limit="873.22"/>
                    <measurement group_id="O8" value="682.37" lower_limit="601.34" upper_limit="774.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1709.46" lower_limit="1373.92" upper_limit="2126.94"/>
                    <measurement group_id="O2" value="1685.31" lower_limit="1318.70" upper_limit="2153.85"/>
                    <measurement group_id="O3" value="1493.37" lower_limit="1144.92" upper_limit="1947.88"/>
                    <measurement group_id="O4" value="844.62" lower_limit="736.10" upper_limit="969.13"/>
                    <measurement group_id="O5" value="764.02" lower_limit="687.93" upper_limit="848.52"/>
                    <measurement group_id="O6" value="820.14" lower_limit="739.90" upper_limit="909.08"/>
                    <measurement group_id="O7" value="939.58" lower_limit="808.92" upper_limit="1091.35"/>
                    <measurement group_id="O8" value="765.74" lower_limit="674.90" upper_limit="868.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiuA Pneumococcal Protein</title>
        <description>MSD Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiuA Pneumococcal Protein</title>
          <description>MSD Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1401.11" lower_limit="895.60" upper_limit="2191.93"/>
                    <measurement group_id="O2" value="1524.31" lower_limit="968.09" upper_limit="2400.10"/>
                    <measurement group_id="O3" value="1625.92" lower_limit="923.10" upper_limit="2863.84"/>
                    <measurement group_id="O4" value="677.28" lower_limit="535.39" upper_limit="856.78"/>
                    <measurement group_id="O5" value="575.24" lower_limit="449.63" upper_limit="735.94"/>
                    <measurement group_id="O6" value="556.30" lower_limit="442.49" upper_limit="699.38"/>
                    <measurement group_id="O7" value="679.07" lower_limit="530.85" upper_limit="868.68"/>
                    <measurement group_id="O8" value="601.79" lower_limit="474.76" upper_limit="762.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1471.39" lower_limit="981.61" upper_limit="2205.56"/>
                    <measurement group_id="O2" value="1668.22" lower_limit="1077.75" upper_limit="2582.20"/>
                    <measurement group_id="O3" value="1603.96" lower_limit="1003.56" upper_limit="2563.53"/>
                    <measurement group_id="O4" value="837.32" lower_limit="659.76" upper_limit="1062.66"/>
                    <measurement group_id="O5" value="732.41" lower_limit="597.09" upper_limit="898.41"/>
                    <measurement group_id="O6" value="702.78" lower_limit="577.60" upper_limit="855.08"/>
                    <measurement group_id="O7" value="860.69" lower_limit="672.04" upper_limit="1102.30"/>
                    <measurement group_id="O8" value="671.40" lower_limit="526.98" upper_limit="855.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1582.79" lower_limit="1021.39" upper_limit="2452.74"/>
                    <measurement group_id="O2" value="1898.28" lower_limit="1189.21" upper_limit="3030.13"/>
                    <measurement group_id="O3" value="1769.43" lower_limit="1111.95" upper_limit="2815.66"/>
                    <measurement group_id="O4" value="937.83" lower_limit="730.15" upper_limit="1204.57"/>
                    <measurement group_id="O5" value="815.05" lower_limit="662.34" upper_limit="1002.96"/>
                    <measurement group_id="O6" value="961.01" lower_limit="804.64" upper_limit="1147.77"/>
                    <measurement group_id="O7" value="1108.83" lower_limit="880.94" upper_limit="1395.67"/>
                    <measurement group_id="O8" value="763.13" lower_limit="612.16" upper_limit="951.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiaA Pneumococcal Protein</title>
        <description>MSD Assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Cohort: PATH-wSP (600 mcg)</title>
            <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O2">
            <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
            <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
          </group>
          <group group_id="O3">
            <title>Adult Cohort: Saline</title>
            <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O7">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O8">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiaA Pneumococcal Protein</title>
          <description>MSD Assay</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1933.77" lower_limit="1248.16" upper_limit="2995.98"/>
                    <measurement group_id="O2" value="2027.06" lower_limit="1481.10" upper_limit="2774.27"/>
                    <measurement group_id="O3" value="1897.23" lower_limit="1211.22" upper_limit="2971.80"/>
                    <measurement group_id="O4" value="650.98" lower_limit="503.48" upper_limit="841.69"/>
                    <measurement group_id="O5" value="503.78" lower_limit="373.57" upper_limit="679.38"/>
                    <measurement group_id="O6" value="609.28" lower_limit="476.06" upper_limit="779.79"/>
                    <measurement group_id="O7" value="892.24" lower_limit="715.63" upper_limit="1112.42"/>
                    <measurement group_id="O8" value="542.93" lower_limit="430.61" upper_limit="684.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2299.24" lower_limit="1449.89" upper_limit="3646.14"/>
                    <measurement group_id="O2" value="2396.09" lower_limit="1745.84" upper_limit="3288.52"/>
                    <measurement group_id="O3" value="1853.17" lower_limit="1231.25" upper_limit="2789.21"/>
                    <measurement group_id="O4" value="759.91" lower_limit="605.92" upper_limit="953.04"/>
                    <measurement group_id="O5" value="622.89" lower_limit="485.14" upper_limit="799.76"/>
                    <measurement group_id="O6" value="721.16" lower_limit="578.45" upper_limit="899.08"/>
                    <measurement group_id="O7" value="1197.63" lower_limit="951.41" upper_limit="1507.56"/>
                    <measurement group_id="O8" value="602.56" lower_limit="476.30" upper_limit="762.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2471.44" lower_limit="1620.81" upper_limit="3768.50"/>
                    <measurement group_id="O2" value="2875.72" lower_limit="2003.45" upper_limit="4127.76"/>
                    <measurement group_id="O3" value="2218.47" lower_limit="1548.56" upper_limit="3178.18"/>
                    <measurement group_id="O4" value="926.53" lower_limit="714.91" upper_limit="1200.79"/>
                    <measurement group_id="O5" value="833.02" lower_limit="653.96" upper_limit="1061.12"/>
                    <measurement group_id="O6" value="880.18" lower_limit="718.66" upper_limit="1078.02"/>
                    <measurement group_id="O7" value="1493.50" lower_limit="1179.45" upper_limit="1891.16"/>
                    <measurement group_id="O8" value="750.60" lower_limit="580.03" upper_limit="971.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA</title>
        <description>Measured using ELISA</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA</title>
          <description>Measured using ELISA</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="1.10" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.63" lower_limit="1.34" upper_limit="1.98"/>
                    <measurement group_id="O3" value="1.19" lower_limit="1.03" upper_limit="1.37"/>
                    <measurement group_id="O4" value="1.94" lower_limit="1.63" upper_limit="2.31"/>
                    <measurement group_id="O5" value="1.07" lower_limit="0.89" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.60" upper_limit="2.49"/>
                    <measurement group_id="O2" value="2.35" lower_limit="1.86" upper_limit="2.98"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.57" upper_limit="2.54"/>
                    <measurement group_id="O4" value="2.48" lower_limit="1.88" upper_limit="3.28"/>
                    <measurement group_id="O5" value="1.16" lower_limit="0.98" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA</title>
        <description>Measured using ELISA</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA</title>
          <description>Measured using ELISA</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="1.09" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.28" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.96" upper_limit="1.40"/>
                    <measurement group_id="O4" value="1.67" lower_limit="1.26" upper_limit="2.21"/>
                    <measurement group_id="O5" value="0.91" lower_limit="0.79" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" lower_limit="1.39" upper_limit="2.24"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.20" upper_limit="1.87"/>
                    <measurement group_id="O3" value="1.62" lower_limit="1.29" upper_limit="2.03"/>
                    <measurement group_id="O4" value="1.83" lower_limit="1.34" upper_limit="2.49"/>
                    <measurement group_id="O5" value="1.07" lower_limit="0.83" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: MSD</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: MSD</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.11" upper_limit="1.40"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.37" upper_limit="1.77"/>
                    <measurement group_id="O3" value="1.25" lower_limit="1.14" upper_limit="1.37"/>
                    <measurement group_id="O4" value="1.82" lower_limit="1.57" upper_limit="2.11"/>
                    <measurement group_id="O5" value="1.14" lower_limit="1.01" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.47" upper_limit="2.01"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.66" upper_limit="2.31"/>
                    <measurement group_id="O3" value="2.04" lower_limit="1.72" upper_limit="2.42"/>
                    <measurement group_id="O4" value="2.40" lower_limit="1.98" upper_limit="2.92"/>
                    <measurement group_id="O5" value="1.28" lower_limit="1.11" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: MSD</title>
        <description>Measured using ELISA</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: MSD</title>
          <description>Measured using ELISA</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="1.24" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.48" upper_limit="2.04"/>
                    <measurement group_id="O3" value="1.34" lower_limit="1.10" upper_limit="1.64"/>
                    <measurement group_id="O4" value="1.94" lower_limit="1.44" upper_limit="2.60"/>
                    <measurement group_id="O5" value="0.94" lower_limit="0.80" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.58" upper_limit="2.77"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.57" upper_limit="2.47"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.46" upper_limit="2.29"/>
                    <measurement group_id="O4" value="2.38" lower_limit="1.71" upper_limit="3.31"/>
                    <measurement group_id="O5" value="1.03" lower_limit="0.80" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PhtD Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PhtD Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.16" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.11" upper_limit="1.42"/>
                    <measurement group_id="O3" value="1.24" lower_limit="0.94" upper_limit="1.63"/>
                    <measurement group_id="O4" value="1.32" lower_limit="1.11" upper_limit="1.55"/>
                    <measurement group_id="O5" value="1.18" lower_limit="1.04" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.53" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.90" lower_limit="1.55" upper_limit="2.32"/>
                    <measurement group_id="O3" value="1.65" lower_limit="1.29" upper_limit="2.11"/>
                    <measurement group_id="O4" value="2.10" lower_limit="1.73" upper_limit="2.56"/>
                    <measurement group_id="O5" value="1.60" lower_limit="1.28" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against BCH0785 Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against BCH0785 Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.10" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.30" lower_limit="1.12" upper_limit="1.51"/>
                    <measurement group_id="O3" value="1.33" lower_limit="1.08" upper_limit="1.63"/>
                    <measurement group_id="O4" value="1.41" lower_limit="1.17" upper_limit="1.71"/>
                    <measurement group_id="O5" value="1.14" lower_limit="1.00" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="1.14" upper_limit="1.63"/>
                    <measurement group_id="O2" value="1.70" lower_limit="1.41" upper_limit="2.05"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.34" upper_limit="2.07"/>
                    <measurement group_id="O4" value="1.93" lower_limit="1.53" upper_limit="2.42"/>
                    <measurement group_id="O5" value="1.31" lower_limit="1.05" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against StkP Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against StkP Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="1.19" upper_limit="1.56"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.09" upper_limit="1.46"/>
                    <measurement group_id="O3" value="1.19" lower_limit="1.00" upper_limit="1.42"/>
                    <measurement group_id="O4" value="1.29" lower_limit="1.12" upper_limit="1.48"/>
                    <measurement group_id="O5" value="1.12" lower_limit="1.00" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.44" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.52" upper_limit="2.12"/>
                    <measurement group_id="O3" value="1.74" lower_limit="1.40" upper_limit="2.15"/>
                    <measurement group_id="O4" value="1.67" lower_limit="1.40" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.29" lower_limit="1.12" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PcpA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PcpA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.91" upper_limit="1.39"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.83" upper_limit="1.10"/>
                    <measurement group_id="O3" value="1.33" lower_limit="0.95" upper_limit="1.87"/>
                    <measurement group_id="O4" value="0.97" lower_limit="0.73" upper_limit="1.28"/>
                    <measurement group_id="O5" value="1.17" lower_limit="0.96" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.91" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.82" upper_limit="1.39"/>
                    <measurement group_id="O3" value="1.24" lower_limit="0.92" upper_limit="1.68"/>
                    <measurement group_id="O4" value="1.17" lower_limit="0.80" upper_limit="1.72"/>
                    <measurement group_id="O5" value="1.43" lower_limit="1.03" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against SPWCA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against SPWCA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.06" upper_limit="1.30"/>
                    <measurement group_id="O2" value="1.14" lower_limit="1.02" upper_limit="1.27"/>
                    <measurement group_id="O3" value="1.18" lower_limit="1.05" upper_limit="1.34"/>
                    <measurement group_id="O4" value="1.16" lower_limit="1.03" upper_limit="1.30"/>
                    <measurement group_id="O5" value="1.05" lower_limit="0.94" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.11" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1.10" upper_limit="1.38"/>
                    <measurement group_id="O3" value="1.33" lower_limit="1.17" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.43" lower_limit="1.24" upper_limit="1.66"/>
                    <measurement group_id="O5" value="1.17" lower_limit="1.04" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PiuA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PiuA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="1.08" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.08" upper_limit="1.47"/>
                    <measurement group_id="O3" value="1.26" lower_limit="1.05" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.27" lower_limit="1.11" upper_limit="1.45"/>
                    <measurement group_id="O5" value="1.12" lower_limit="1.01" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="1.14" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.23" upper_limit="1.74"/>
                    <measurement group_id="O3" value="1.73" lower_limit="1.38" upper_limit="2.16"/>
                    <measurement group_id="O4" value="1.64" lower_limit="1.37" upper_limit="1.96"/>
                    <measurement group_id="O5" value="1.24" lower_limit="1.07" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of IgG Antibodies Against PiaA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>The number analyzed may differ between periods because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Toddler Cohort: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of IgG Antibodies Against PiaA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <population>The number analyzed may differ between periods because of insufficient samples.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.01" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1.03" upper_limit="1.47"/>
                    <measurement group_id="O3" value="1.18" lower_limit="1.03" upper_limit="1.37"/>
                    <measurement group_id="O4" value="1.34" lower_limit="1.15" upper_limit="1.57"/>
                    <measurement group_id="O5" value="1.11" lower_limit="0.98" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" lower_limit="1.15" upper_limit="1.70"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.32" upper_limit="2.16"/>
                    <measurement group_id="O3" value="1.44" lower_limit="1.20" upper_limit="1.73"/>
                    <measurement group_id="O4" value="1.66" lower_limit="1.34" upper_limit="2.05"/>
                    <measurement group_id="O5" value="1.34" lower_limit="1.11" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to Pneumolysoid (L460D) Pneumococcal Protein Among Toddler Cohort (ELISA)</title>
        <description>Measured using ELISA</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to Pneumolysoid (L460D) Pneumococcal Protein Among Toddler Cohort (ELISA)</title>
          <description>Measured using ELISA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="45"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="33"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PspA-Fam1 (ELISA)</title>
        <description>Measured using ELISA</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PspA-Fam1 (ELISA)</title>
          <description>Measured using ELISA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to L460D Pneumococcal Protein (MSD)</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to L460D Pneumococcal Protein (MSD)</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PspA-Fam1 Pneumococcal Protein (MSD)</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PspA-Fam1 Pneumococcal Protein (MSD)</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PhtD Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PhtD Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to BCH0785 Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to BCH0785 Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to StkP Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to StkP Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PcpA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PcpA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="26"/>
                    <measurement group_id="O10" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to SPWCA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to SPWCA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PiuA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PiuA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in IgG Response to PiaA Pneumococcal Protein</title>
        <description>Measured using MSD</description>
        <time_frame>28 days (post-vaccination 1) and 56 days (post-vaccination 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 300 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Single injection of 600 mcg PATH-wSP in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh.</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only: Vaccination 1</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh 8 weeks after the first vaccination of the same dosage plus two active control vaccines in the right thigh.</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Injection of PATH-wSP 300 mcg in the left thigh, 8 weeks after the first vaccination of the same plus a saline injection in the right thigh.</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh, 8 weeks after the first vaccination of the same dosage and two active control vaccinations in the right thigh</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>A single injection of 600 mcg PATH-wSP in the left thigh, 8 weeks after receipt of vaccination of the same dosage and two saline injections in the right thigh.</description>
          </group>
          <group group_id="O10">
            <title>Active Control Only: Vaccination 2</title>
            <description>A single injection of saline in the left thigh, 8 weeks after the same saline injection plus a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in IgG Response to PiaA Pneumococcal Protein</title>
          <description>Measured using MSD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;2-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2-Fold, &lt;3-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3-Fold, &lt;4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥4-Fold</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Adult Subjects With Neutralizing Antibody Response to Pneumolysin</title>
        <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (600 mcg): Baseline</title>
            <description>Subjects receiving 600 mcg PATH-wSP: levels pre-vaccination</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (600 mcg): Vaccination 1</title>
            <description>Subjects receiving 600 mcg PATH-wSP: levels after first vaccination</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (600 mcg): Vaccination 2</title>
            <description>Subjects receiving 600 mcg PATH-wSP: levels after second vaccination</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (1000 mcg): Baseline</title>
            <description>Subjects receiving 1000 mcg PATH-wSP: levels pre-vaccination</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (1000 mcg): Vaccination 1</title>
            <description>Subjects receiving 1000 mcg PATH-wSP: levels after first vaccination</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (1000 mcg): Vaccination 2</title>
            <description>Subjects receiving 1000 mcg PATH-wSP: levels after second vaccination</description>
          </group>
          <group group_id="O7">
            <title>Saline: Baseline</title>
            <description>Subjects receiving saline placebo injection: levels pre-vaccination</description>
          </group>
          <group group_id="O8">
            <title>Saline: Vaccination 1</title>
            <description>Subjects receiving saline placebo injection: levels after vaccination 1</description>
          </group>
          <group group_id="O9">
            <title>Saline: Vaccination 2</title>
            <description>Subjects receiving saline placebo injection: levels after vaccination 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Adult Subjects With Neutralizing Antibody Response to Pneumolysin</title>
          <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;1:20</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:20</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:40</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:80</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:160</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Toddler Subjects With Neutralizing Antibody Response to Pneumolysin</title>
        <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP (300 mcg)+Active Control: Baseline</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: pre-vaccination</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 1</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 1</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP (300 mcg)+Active Control: Vaccination 2</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 2</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP (300 mcg)+Saline: Baseline</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: pre-vaccination</description>
          </group>
          <group group_id="O5">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 1</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: after vaccination 1</description>
          </group>
          <group group_id="O6">
            <title>PATH-wSP (300 mcg)+Saline: Vaccination 2</title>
            <description>Subjects receiving 300 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: after vaccination 2</description>
          </group>
          <group group_id="O7">
            <title>PATH-wSP (600 mcg)+Active Control: Baseline</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: pre-vaccination</description>
          </group>
          <group group_id="O8">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 1</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 1</description>
          </group>
          <group group_id="O9">
            <title>PATH-wSP (600 mcg)+Active Control: Vaccination 2</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 2</description>
          </group>
          <group group_id="O10">
            <title>PATH-wSP (600 mcg)+Saline: Baseline</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: pre-vaccination</description>
          </group>
          <group group_id="O11">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 1</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: after Vaccination 1</description>
          </group>
          <group group_id="O12">
            <title>PATH-wSP (600 mcg)+Saline: Vaccination 2</title>
            <description>Subjects receiving 600 mcg PATH-wSP in the left thigh and two injections of saline placebo in the right thigh: after Vaccination 2</description>
          </group>
          <group group_id="O13">
            <title>Active Control Only: Baseline</title>
            <description>Subjects receiving saline placebo injection in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: pre-vaccination</description>
          </group>
          <group group_id="O14">
            <title>Active Control Only: Vaccination 1</title>
            <description>Subjects receiving saline placebo injection in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 1</description>
          </group>
          <group group_id="O15">
            <title>Active Control Only: Vaccination 2</title>
            <description>Subjects receiving saline placebo injection in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh: after vaccination 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Toddler Subjects With Neutralizing Antibody Response to Pneumolysin</title>
          <description>Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (&lt;1/20) or positive (with titer between 1/20 and 1/320).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="47"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="46"/>
                <count group_id="O13" value="48"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;1:20</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="27"/>
                    <measurement group_id="O14" value="21"/>
                    <measurement group_id="O15" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:20</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="12"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="10"/>
                    <measurement group_id="O14" value="13"/>
                    <measurement group_id="O15" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:40</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="13"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="11"/>
                    <measurement group_id="O15" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:80</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="11"/>
                    <measurement group_id="O12" value="13"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:160</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:320</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMCs) of PNC-IgG Serotypes Among Toddler Subjects</title>
        <description>GMCs of these IgG proteins were measured to assess potential interference of PATH-wSP with 10-valent pneumococcal conjugate vaccine (Synflorix). GMCs of Cohort 1 were measured at a different time point than those in Cohort 2, so results are presented separately.</description>
        <time_frame>12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMCs) of PNC-IgG Serotypes Among Toddler Subjects</title>
          <description>GMCs of these IgG proteins were measured to assess potential interference of PATH-wSP with 10-valent pneumococcal conjugate vaccine (Synflorix). GMCs of Cohort 1 were measured at a different time point than those in Cohort 2, so results are presented separately.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PnC-IgG-ELISA type 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.72" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.14" upper_limit="0.21"/>
                    <measurement group_id="O3" value="3.09" lower_limit="2.50" upper_limit="3.83"/>
                    <measurement group_id="O4" value="0.25" lower_limit="0.21" upper_limit="0.30"/>
                    <measurement group_id="O5" value="0.83" lower_limit="0.64" upper_limit="1.08"/>
                    <measurement group_id="O6" value="2.47" lower_limit="1.81" upper_limit="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="1.01" upper_limit="1.47"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.22" upper_limit="0.34"/>
                    <measurement group_id="O3" value="3.41" lower_limit="2.93" upper_limit="3.96"/>
                    <measurement group_id="O4" value="0.36" lower_limit="0.29" upper_limit="0.46"/>
                    <measurement group_id="O5" value="1.15" lower_limit="0.89" upper_limit="1.50"/>
                    <measurement group_id="O6" value="2.59" lower_limit="2.08" upper_limit="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.32" upper_limit="0.45"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.20"/>
                    <measurement group_id="O3" value="0.77" lower_limit="0.64" upper_limit="0.92"/>
                    <measurement group_id="O4" value="0.19" lower_limit="0.16" upper_limit="0.23"/>
                    <measurement group_id="O5" value="0.44" lower_limit="0.33" upper_limit="0.58"/>
                    <measurement group_id="O6" value="0.77" lower_limit="0.65" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.33" upper_limit="1.92"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.54" upper_limit="0.88"/>
                    <measurement group_id="O3" value="4.28" lower_limit="3.48" upper_limit="5.27"/>
                    <measurement group_id="O4" value="0.95" lower_limit="0.76" upper_limit="1.18"/>
                    <measurement group_id="O5" value="2.19" lower_limit="1.62" upper_limit="2.94"/>
                    <measurement group_id="O6" value="3.68" lower_limit="2.68" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.48" upper_limit="2.16"/>
                    <measurement group_id="O2" value="0.60" lower_limit="0.50" upper_limit="0.72"/>
                    <measurement group_id="O3" value="4.32" lower_limit="3.63" upper_limit="5.13"/>
                    <measurement group_id="O4" value="0.72" lower_limit="0.59" upper_limit="0.89"/>
                    <measurement group_id="O5" value="1.36" lower_limit="1.04" upper_limit="1.79"/>
                    <measurement group_id="O6" value="3.57" lower_limit="2.97" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.65" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.20" upper_limit="0.33"/>
                    <measurement group_id="O3" value="2.03" lower_limit="1.73" upper_limit="2.38"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.24" upper_limit="0.35"/>
                    <measurement group_id="O5" value="0.71" lower_limit="0.51" upper_limit="0.97"/>
                    <measurement group_id="O6" value="1.57" lower_limit="1.25" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="2.54" upper_limit="3.92"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.50" upper_limit="0.78"/>
                    <measurement group_id="O3" value="8.62" lower_limit="7.02" upper_limit="10.57"/>
                    <measurement group_id="O4" value="1.02" lower_limit="0.79" upper_limit="1.33"/>
                    <measurement group_id="O5" value="3.20" lower_limit="2.36" upper_limit="4.34"/>
                    <measurement group_id="O6" value="7.40" lower_limit="5.37" upper_limit="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.25" upper_limit="1.82"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.22" upper_limit="0.35"/>
                    <measurement group_id="O3" value="3.52" lower_limit="3.00" upper_limit="4.13"/>
                    <measurement group_id="O4" value="0.33" lower_limit="0.27" upper_limit="0.41"/>
                    <measurement group_id="O5" value="1.31" lower_limit="1.00" upper_limit="1.71"/>
                    <measurement group_id="O6" value="3.05" lower_limit="2.43" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="3.78" upper_limit="5.63"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.08" upper_limit="2.02"/>
                    <measurement group_id="O3" value="10.93" lower_limit="8.92" upper_limit="13.38"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.17" upper_limit="1.93"/>
                    <measurement group_id="O5" value="4.76" lower_limit="3.33" upper_limit="6.80"/>
                    <measurement group_id="O6" value="7.59" lower_limit="5.10" upper_limit="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PnC-IgG-ELISA type 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.77" upper_limit="1.25"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0.21" upper_limit="0.35"/>
                    <measurement group_id="O3" value="2.76" lower_limit="2.22" upper_limit="3.44"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.21" upper_limit="0.37"/>
                    <measurement group_id="O5" value="0.97" lower_limit="0.70" upper_limit="1.34"/>
                    <measurement group_id="O6" value="3.50" lower_limit="2.60" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Diptheria Booster Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Diptheria Booster Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" lower_limit="6.38" upper_limit="9.36"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.20" upper_limit="0.32"/>
                    <measurement group_id="O3" value="7.71" lower_limit="6.48" upper_limit="9.19"/>
                    <measurement group_id="O4" value="0.27" lower_limit="0.22" upper_limit="0.33"/>
                    <measurement group_id="O5" value="9.39" lower_limit="7.90" upper_limit="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Hepatitis B Booster Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Hepatitis B Booster Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784.78" lower_limit="532.71" upper_limit="11156.12"/>
                    <measurement group_id="O2" value="149.86" lower_limit="83.65" upper_limit="268.47"/>
                    <measurement group_id="O3" value="695.14" lower_limit="546.72" upper_limit="883.84"/>
                    <measurement group_id="O4" value="135.79" lower_limit="84.93" upper_limit="217.11"/>
                    <measurement group_id="O5" value="815.39" lower_limit="705.76" upper_limit="942.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Haemophilus Influenzae Type b (Hib) Booster Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Haemophilus Influenzae Type b (Hib) Booster Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.05" lower_limit="29.61" upper_limit="56.92"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.20" upper_limit="2.34"/>
                    <measurement group_id="O3" value="39.06" lower_limit="30.70" upper_limit="49.68"/>
                    <measurement group_id="O4" value="1.23" lower_limit="0.81" upper_limit="1.88"/>
                    <measurement group_id="O5" value="37.45" lower_limit="25.82" upper_limit="54.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Pertussis FHA and Pertussis Toxin Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Pertussis FHA and Pertussis Toxin Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.12" lower_limit="73.07" upper_limit="99.17"/>
                    <measurement group_id="O2" value="6.70" lower_limit="5.48" upper_limit="8.21"/>
                    <measurement group_id="O3" value="68.23" lower_limit="57.45" upper_limit="81.05"/>
                    <measurement group_id="O4" value="10.47" lower_limit="8.40" upper_limit="13.05"/>
                    <measurement group_id="O5" value="90.65" lower_limit="73.87" upper_limit="111.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis Toxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.11" lower_limit="121.66" upper_limit="173.08"/>
                    <measurement group_id="O2" value="19.38" lower_limit="15.13" upper_limit="24.81"/>
                    <measurement group_id="O3" value="131.23" lower_limit="105.83" upper_limit="162.73"/>
                    <measurement group_id="O4" value="18.79" lower_limit="13.55" upper_limit="26.07"/>
                    <measurement group_id="O5" value="124.39" lower_limit="96.63" upper_limit="160.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Pertussis Fimbriae Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Pertussis Fimbriae Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="753.63" lower_limit="582.34" upper_limit="975.30"/>
                    <measurement group_id="O2" value="45.75" lower_limit="32.98" upper_limit="63.47"/>
                    <measurement group_id="O3" value="460.73" lower_limit="328.95" upper_limit="645.31"/>
                    <measurement group_id="O4" value="37.99" lower_limit="27.75" upper_limit="52.00"/>
                    <measurement group_id="O5" value="503.25" lower_limit="383.05" upper_limit="661.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) Ratio of Tetanus Booster Immune Response Among Toddler Subjects</title>
        <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
        <time_frame>12 weeks post vaccination 1</time_frame>
        <population>The number analyzed may differ between proteins because of insufficient samples.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 mcg+Saline</title>
            <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 mcg+Active Control</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 mcg+Saline</title>
            <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
PATH-wSP: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Saline: 0.9% Sodium Chloride Injection, USP</description>
          </group>
          <group group_id="O5">
            <title>Active Control Only</title>
            <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Synflorix: 1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Pentavac: Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 %
Dose:</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) Ratio of Tetanus Booster Immune Response Among Toddler Subjects</title>
          <description>GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.</description>
          <population>The number analyzed may differ between proteins because of insufficient samples.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.83" lower_limit="18.94" upper_limit="25.17"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0.93" upper_limit="1.43"/>
                    <measurement group_id="O3" value="21.64" lower_limit="19.01" upper_limit="24.62"/>
                    <measurement group_id="O4" value="1.27" lower_limit="1.03" upper_limit="1.55"/>
                    <measurement group_id="O5" value="21.92" lower_limit="18.95" upper_limit="25.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks post-vaccination</time_frame>
      <desc>Subjects returned to the clinic 1 week post each vaccination and at 4 weeks after the final vaccination for assessment of solicited reactogenicity, targeted physical examination, vital signs, laboratory assessment, immunology testing, and evaluation for unsolicited AEs and concomitant medication use.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adult Cohort: PATH-wSP (600 mcg)</title>
          <description>A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="E2">
          <title>Adult Cohort: PATH-wSP (1000 mcg)</title>
          <description>A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.</description>
        </group>
        <group group_id="E3">
          <title>Adult Cohort: Saline</title>
          <description>A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.</description>
        </group>
        <group group_id="E4">
          <title>Toddler Cohort: PATH-wSP (300 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="E5">
          <title>Toddler Cohort: PATH-wSP (300 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="E6">
          <title>Toddler Cohort: PATH-wSP (600 mcg)+Active Control</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="E7">
          <title>Toddler Cohort: PATH-wSP (600 mcg)+Saline</title>
          <description>A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.</description>
        </group>
        <group group_id="E8">
          <title>Toddler Cohort: Active Control Only</title>
          <description>A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="48" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Septic rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="43" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="43" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

